Savvy Trades and Investments

[researcher59]

GERN +.43 to 4.22, a six year high after Cowen initiates coverage with a $10 price target -

fly -

TD Cowen initiated coverage of Geron with a Buy rating and $10 price target. The firm says imetelstat is disease-modifying with the most durable transfusion independence it has seen in lower risk myelodysplastic syndromes. The drug also works broadly and can address currently underserved patient populations upon potential approval in June, which is as likely based on the 12-2 FDA panel vote, the analyst tells investors in a research note. Further, success in high-risk myelofibrosis could double imetelstat's opportunity, contends TD.